Gabriele Köhl

Gabriele Köhl

Auto-generated profile, based on publicly available information

Gabriele Köhl

Institute for Systemic Inflammation Research University of Lübeck Lübeck Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2023 in The Journal of Pathology
Verified
Journal Article
Open access
MPManuela Pigors
Manuela Pigors
SPSabrina Patzelt
Sabrina Patzelt
NRNiklas Reichhelm
Niklas Reichhelm
JDJenny Dworschak
Jenny Dworschak
SKStanislav Khil'CHenko
Stanislav Khil'CHenko
ESEnno Schmidt
Enno Schmidt
Bullous pemphigoid (BP) is an autoimmune blistering disease characterized by autoantibodies targeting type XVII collagen (Col17) with the noncollagenous 16A (NC16A) ectodomain representing the immunodominant site. The role of additional extracellular targets of Col17 outside NC16A has not been unequivocally demonstrated. In this study, we showed that Col17 ectodomain‐reactive patient sera depleted in NC16A IgG induced dermal–epidermal separation in a cryosection model indicating the pathogenic potential of anti‐Col17 non‐NC16A extracellular IgG. Moreover, injection of IgG targeting the murine Col17 NC14–1 domains (downstream of NC15A, the murine homologue of human NC16A) into C57BL/6J mice resulted in erythematous skin lesions and erosions. Clinical findings were accompanied by IgG/C3 deposits along the basement membrane and subepidermal blistering with inflammatory infiltrates. Disease development was significantly reduced in either Fc‐gamma receptor (FcγR)‐ or complement‐5a receptor‐1 (C5aR1)‐deficient mice. Inhibition of the neonatal FcR (FcRn), an atypical FcγR regulating IgG homeostasis, with the murine Fc fragment IgG2c‐ABDEG, a derivative of efgartigimod, reduced anti‐NC14–1 IgG levels, resulting in ameliorated skin inflammation compared with isotype‐treated controls. These data demonstrate that the pathogenic effects of IgG targeting the Col17 domain outside human NC16A/murine NC15A are partly attributable to antibody‐mediated FcγR‐ and C5aR1 effector mechanisms while pharmacological inhibition of the FcRn represents a promising treatment for BP. The mouse model of BP will be instrumental in further investigating the role of Col17 non‐NC16A/NC15A extracellular epitopes and validating new therapies for this disease. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

1 February 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
ACAnn-Katrin Clauder
Ann-Katrin Clauder
AKAnna Kordowski
Anna Kordowski
YBYannic C. Bartsch
Yannic C. Bartsch
GKGabriele Köhl
Gabriele Köhl
GLGina-Maria Lilienthal
Gina-Maria Lilienthal
RMRudolf Armin Manz
Rudolf Armin Manz